Breaking News

Samsung Biologics Launches Virtual Showroom

Provides key features and real-time construction updates of its recently announced Plant 4.

By: Contract Pharma

Contract Pharma Staff

Samsung Biologics has launched a virtual showroom to provide key features and real-time construction updates of its recently announced Plant 4. The digital showcase also highlights various specs and services that the Super Plant will offer upon completion.
 
The Plant 4 Virtual Showroom mirrors the company’s commitment to leading the industry’s technology innovation and its enhanced digital strategy to deliver client satisfaction and present manufacturing services in a highly optimized format. The showroom will also allow Samsung Biologics’ teams to connect and respond quickly to clients’ interests and inquiries about the new facility, digitally.  
 
The company’s new plant, which officially broke ground last month, will be one of the world’s largest and most innovative bio-manufacturing facilities of its kind upon completion, holding a total capacity of 256,000 liters.
 
Expanding to Meet Accelerated Demand
 
The company’s decision to accelerate its plans to build a fourth plant was driven by the significant growth Samsung Biologics experienced during the Covid-19 pandemic, including signing over 1.8 trillion KRW in orders in the first half of 2020 alone. In addition, the company announced several high-profile partnerships with biopharmaceutical companies such as AstraZeneca, GlaxoSmithKline, and Eli Lilly this year.
 
“Our new Super Plant and our virtual showroom are a direct response to an accelerated demand in the industry for both traditional and digitally enabled services. By leveraging the latest innovation, Plant 4 will provide easy and secure access to manufacturing and quality information whenever customers require it and deliver the highest levels of client satisfaction and regulatory compliance,” Dr. Tae Han Kim, CEO of Samsung Biologics said. “Our Plant 4 Virtual Showroom also exemplifies Samsung Biologics’ latest efforts to lead the industry in the digital revolution for enhanced connectivity and agility in responding to our clients, partners, and shareholders.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters